Thermo Fisher’s clinical research subsidiary, PPD, invests $59 million in sample management and testing capacity for vaccines and cell and gene therapy products with its expansion of laboratory operations in Kentucky.
PPD’s Evidera business unit is set to acquire Medimix International, a global technology company with a real-world evidence service offering that includes access to patient-level data, data analytics, and visualization capabilities.
Patient centricity quite plainly means to put the patient at the “front and center,” explained Rhonda Henry, vice president, site collaborations and patient centricity, PPD – though many remain confused on how to be “patient centric.”
CROs Pharmaceutical Product Development (PPD) and ERT on Tuesday announced a strategic partnership to deliver ERT’s patient safety and efficacy endpoint data collection tools to help biopharma clients conduct clinical trials in a more efficient and cost-effective...
PPD’s acquisition of Merck’s vaccine testing laboratory will give it a geographic location from which it can compete for business with its “number one competitor”, which is well established in the north east of the US.
Contract research organisation PPD has boosted its compound partnering programme with the purchase of dermatology specialist Magen BioSciences, and divested its presclinical research subsidiary Pedmont Research Centre.
Pharmaceutical Product Development of the US is expecting to post a 12 per cent hike in revenues in 2009, helped by the recent opening of offices in Ireland and Singapore and new deals with Merck & Co.
Pharmaceutical Products Development (PPD) has announced it is
moving into Russia, along with the news of positive trial results
for its statin, although profits dipped again during the fourth
quarter of 2007 as its R&D bill mounts.
As global contract research spending remains robust, business is
booming for Pharmaceutical Product Development (PPD) as the US firm
reported a surge in sales, profits and new business for its second
PPD managed a 42 per cent jump in pre-tax profit to the tune of
$63.8m (€50.1m) in the first quarter, fuelled by a strong growth in
new clinical trials business and helped by a milestone payment in
the discovery sciences segment.